New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs

Česká verzia

Authors: J. Malý ¹; M. Pecka ¹; R. Malý ²
Authors place of work: II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ¹; I. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jan Vojáček, DrSc., FESC, FACC ²
Published in the journal: Vnitř Lék 2011; 57(9): 733-739
Category: 65th birthday Mudr. Jany Laciné and and 60th birthday Milana Tržila

Summary

We first present a brief overview of new antithrombotic agents that are assumed to replace coumarines and heparin in many indications; this overview provides information on pentasaccharides, direct thrombin inhibitors and direct factor Xa inhibitors. Secondly, since the new drugs with antiplatelet effect act through blockade of the reactions involved in blood platelet activation, we review and discuss the substances that interfere with this process. The current antiplatelet therapy focuses mainly on an inhibition of platelet aggregation stimulated by ADP, reducing the risk of arterial occlusions.

Key words:
fondaparinux – dabigatran – rivaroxaban – antiplatelet drugs

Zdroje

1. Walenga JM, Jeske WP, Bara L et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1–36.

2. Turpie AG, Bauer KA, Eriksson BI et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833–1840.

3. Singelyn FJ, Verheyen CC, Piovella F et al. EXPERT Study Investigators. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 2007; 105: 1540–1547.

4. Colwell CW Jr, Kwong LM, Turpie AG et al. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21: 36–45.

5. Agnelli G, Bergqvist D, Cohen AT et al. PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212–1220.

6. Büller HR, Davidson BL, Decousus H et al. Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867–873.

7. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003; 254: 322–334.

8. Schulman S, Kearon C, Kakkar AK et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.

9. Connolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators: Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139–1151.

10. Karetová D, Bultas J. Nová antikoagulancia v prevenci a léčbě kardiovaskulárních chorob. Postgrad Med 2010; 1: 72–77.

11. Ruff CT, Giugliano RP. New oral antithrombotic strategies. Hot Topics Cardiol 2009; 18: 7–14.

12. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116–1127.

13. Stangier J, Stähle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47–59.

14. Eriksson BI, Dahl OE, Rosencher N et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178–2185.

15. Eriksson BI, Dahl OE, Rosencher N et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 946–956.

16. Lohrmann J, Becker RC. New anticoagulants – the path from discovery to clinical practice. N Engl J Med 2008; 358: 2827–2829.

17. Eriksson BI, Borris LC, Friedman RJ et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765–2775.

18. Lassen MR, Ageno W, Borris LC et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–2786.

19. Kakkar AK, Brenner B, Dahl OE et al. RECORD 2 investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008; 372: 31–39.

20. Turpie AGG, Lassen MR, Davidson BL et al. RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673–1680.

21. Darius H. Oral rivaroxaban versus standard therapy for the acute and treatment ofsymptomatic deep vein thrombosis. The EINSTEIN DVT study. http://www.escardio.org/congresses/esc-2010/congress-reports/Documents/Tuesday/EINSTEIN-DVTdiscussant-slides-Darius.pdf.

22. Buller HR. Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous thromboembolism. The Einstein-Extension Study. http://ash.confex.com/ash/2009/webprogram/Pap.

23. Mahaffey KW, Fox KAA. ROCKET AF Investigators. Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation. https://www.dcri.org/news-publications/.

24. Varon D, Spectre G. Antiplatelet agents. Hematology Am Soc Hematol Educ Program 2009; 1: 267–272.

25. Broos K, Feys HB, De Meyer SF et al. Platelets at work in primary hemostasis. Blood Rev 2011; 25: 155–167.

26. Cattaneo M. ADP receptors antagonists. In: Michelson AD (ed.). Platelets. 2nd ed. San Diego, Calif: Academic Press 2006: 1127–1144.

27. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2007; 5: 577–582.

28. Cattaneo M. New P2Y12 Inhibitors. Circulation 2010; 121: 171–179.

29. Abergel E, Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 2010; 6: 963–977.